Table 1. Checklist for Submission to the NCPE, NICE (STA only), SMC, and AWMSG

<table>
<thead>
<tr>
<th>Requirement</th>
<th>NCPE</th>
<th>NICE STA</th>
<th>SMC</th>
<th>AWMSG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease outcome information</td>
<td>No</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Economic analysis and regulatory context factors</td>
<td>No</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Systematic review of relevant clinical data for the technology and its comparisons, including a systematic search strategy and development of a Quality of Reporting of Meta-analyses (QUOROM) statement flow diagram</td>
<td>No</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Critical appraisal of relevant economic cost-effectiveness data for the technology, including an economic model analysis [6], or an economic model analysis [7]</td>
<td>No</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Meta-analysis, when appropriate, including assessment of heterogeneity and development of combined results</td>
<td>No</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Indirect and mixed treatment comparisons, if data from head-to-head trials are not available</td>
<td>No</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Interpretation of the clinical evidence</td>
<td>No</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Cost-effectiveness analysis</td>
<td>X</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Description of the patient population</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Description of the model structure</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Description of the technology and comparator</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Systematic review of HRQOL data</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Health status measures</td>
<td>EQ-5D data not essential</td>
<td>Preference for EQ-5D collected from patients</td>
<td>Preference for validated generic utility instruments (such as the EQ-5D)</td>
<td>EQ-5D data not essential</td>
</tr>
<tr>
<td>Systematic review of resource use data</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Cost-effectiveness acceptability curves, including cost-effectiveness acceptability cut-offs</td>
<td>Not essential</td>
<td>Not essential</td>
<td>Not essential</td>
<td>Not essential</td>
</tr>
<tr>
<td>Budget impact analysis</td>
<td>No</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

**Table Notes:**
- A ✓ indicates that the information is required.
- A ✗ indicates that the information is not required.
- A - indicates that the information is not relevant.

**References:**

**CONCLUSIONS**
- Rates of success vary among different HTA bodies, although there appears to be a direct correlation between the level of detail provided in the submission requirements and the likelihood of reimbursement.

**METHODS**
- Examined guidelines for submission of an HTA dossier, as issued by the NCPE, NICE STA, SMC, and AWMSG, on their respective Web sites.
- Excluded the following submitters from the analysis:
  - NCPE multiple technology appraisals (only single technology appraisals included)
  - Resubmissions

**RESULTS**
- Requirements for HTAs (Table 1)
- Economic analysis is a key part of an NCPE submission, although there are no specific requirements or templates for clinical data.
- Requirements for the NICE STA are the most stringent, followed by the SMC and AWMSG.
- Both the NICE STA and the SMC require a systematic review of the relevant critical data for the technology and its comparisons, including a systematic search strategy and development of a Quality of Reporting of Meta-analyses (QUOROM) statement flow diagram. The NICE STA and the SMC submissions also require systematic searches of both resource use and health-related quality of life (HRQOL) data.
- Furthermore, unlike the other HTA bodies investigated, the NICE STA requires a systematic review of relevant cost-effectiveness data for the technology, including a systematic search strategy; a QUOROM statement flow diagram; and a critical appraisal of all relevant randomized controlled trials (RCT) evidence, non-RCT evidence, and cost-effectiveness evaluations.

**DESCRIPTION OF RECENT HTAs SUBMITTED TO THE NCPE, NICE (STA only), SMC, AND AWMSG**

**Figure 1. Summary of Recent Reimbursement Decisions From NCPE, NICE, SMC, AWMSG, and NCPE.**

**Table 1. Checklist for Submission to the NCPE, NICE (STA only), SMC, and AWMSG**

**CONCLUSIONS**
- Rates of success vary among different HTA bodies, although there appears to be a direct correlation between the level of detail provided in the submission requirements and the likelihood of reimbursement.

**REFERENCES**

**CONTACT INFORMATION**
- Catherine Rycroft, PhD
- Senior Associate, Market Access and Outcomes Strategy
- RTI Health Solutions
- Williams House, Manchester Science Park
- Lloyd Street North
- Manchester, M10 0IE
- United Kingdom
- Phone: +44.161.222.4002
- Fax: +44.161.220.3409
- E-mail: crycroft@rti.org
- Presented at: ISPOR 13th Annual European Congress November 6-9, 2010
- Prague, Czech Republic